Alto Neuroscience (ANRO) Competitors $4.60 +0.17 (+3.72%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ANRO vs. SAGE, PHAT, ESPR, ANAB, GHRS, SIGA, TKNO, ZVRA, ATXS, and PRTCShould you be buying Alto Neuroscience stock or one of its competitors? The main competitors of Alto Neuroscience include Sage Therapeutics (SAGE), Phathom Pharmaceuticals (PHAT), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), GH Research (GHRS), SIGA Technologies (SIGA), Alpha Teknova (TKNO), Zevra Therapeutics (ZVRA), Astria Therapeutics (ATXS), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Alto Neuroscience vs. Sage Therapeutics Phathom Pharmaceuticals Esperion Therapeutics AnaptysBio GH Research SIGA Technologies Alpha Teknova Zevra Therapeutics Astria Therapeutics PureTech Health Sage Therapeutics (NASDAQ:SAGE) and Alto Neuroscience (NYSE:ANRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, community ranking, dividends, media sentiment, institutional ownership, profitability, valuation and earnings. Do institutionals & insiders have more ownership in SAGE or ANRO? 99.2% of Sage Therapeutics shares are held by institutional investors. 5.5% of Sage Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate SAGE or ANRO? Sage Therapeutics presently has a consensus target price of $10.53, indicating a potential upside of 48.72%. Alto Neuroscience has a consensus target price of $20.00, indicating a potential upside of 335.26%. Given Alto Neuroscience's stronger consensus rating and higher probable upside, analysts clearly believe Alto Neuroscience is more favorable than Sage Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sage Therapeutics 2 Sell rating(s) 16 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00Alto Neuroscience 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.63 Does the media refer more to SAGE or ANRO? In the previous week, Sage Therapeutics had 7 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Sage Therapeutics and 0 mentions for Alto Neuroscience. Sage Therapeutics' average media sentiment score of 0.40 beat Alto Neuroscience's score of 0.00 indicating that Sage Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sage Therapeutics Neutral Alto Neuroscience Neutral Which has better valuation & earnings, SAGE or ANRO? Alto Neuroscience has lower revenue, but higher earnings than Sage Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSage Therapeutics$106.40M4.07-$541.49M-$5.58-1.27Alto NeuroscienceN/AN/A-$36.31MN/AN/A Is SAGE or ANRO more profitable? Alto Neuroscience has a net margin of 0.00% compared to Sage Therapeutics' net margin of -317.29%. Alto Neuroscience's return on equity of -49.28% beat Sage Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sage Therapeutics-317.29% -50.29% -45.48% Alto Neuroscience N/A -49.28%-33.52% Does the MarketBeat Community believe in SAGE or ANRO? Sage Therapeutics received 618 more outperform votes than Alto Neuroscience when rated by MarketBeat users. However, 82.35% of users gave Alto Neuroscience an outperform vote while only 65.42% of users gave Sage Therapeutics an outperform vote. CompanyUnderperformOutperformSage TherapeuticsOutperform Votes63265.42% Underperform Votes33434.58% Alto NeuroscienceOutperform Votes1482.35% Underperform Votes317.65% SummaryAlto Neuroscience beats Sage Therapeutics on 8 of the 14 factors compared between the two stocks. Get Alto Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ANRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANRO vs. The Competition Export to ExcelMetricAlto NeurosciencePharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$123.93M$6.22B$5.21B$19.94BDividend YieldN/A2.94%5.13%3.71%P/E RatioN/A9.8789.3441.41Price / SalesN/A309.211,240.0416.25Price / CashN/A61.4443.7519.84Price / BookN/A6.055.315.76Net Income-$36.31M$154.90M$122.54M$993.25M7 Day Performance7.36%-0.32%0.59%3.12%1 Month Performance18.12%0.43%2.55%4.75%1 Year PerformanceN/A3.08%25.29%18.83% Alto Neuroscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANROAlto Neuroscience2.5922 of 5 stars$4.60+3.7%$20.00+335.3%N/A$123.93MN/A0.00N/AGap DownSAGESage Therapeutics4.6135 of 5 stars$7.50+35.1%$10.53+40.4%-72.8%$458.80M$106.40M-1.34690High Trading VolumePHATPhathom Pharmaceuticals2.4444 of 5 stars$6.62-4.6%$23.00+247.4%-7.1%$452.66M$26.27M-1.16110Gap DownESPREsperion Therapeutics3.9844 of 5 stars$2.28-2.6%$7.30+220.2%+9.4%$449.24M$295.45M-3.56200ANABAnaptysBio2.8854 of 5 stars$14.62+2.9%$41.45+183.5%-32.5%$444.87M$57.17M-2.40100Gap UpGHRSGH Research1.3767 of 5 stars$8.35-2.6%$35.67+327.1%+51.8%$434.43MN/A-10.5710Short Interest ↑Gap DownSIGASIGA Technologies1.7098 of 5 stars$6.06-2.4%N/A+21.2%$432.71M$173.73M5.0540Positive NewsTKNOAlpha Teknova0.5389 of 5 stars$8.08+0.2%$5.00-38.1%+175.9%$430.73M$36.35M-10.92240ZVRAZevra Therapeutics2.012 of 5 stars$8.06-0.6%$21.57+167.6%+40.7%$430.21M$24.49M-4.0920ATXSAstria Therapeutics1.4925 of 5 stars$7.46+0.1%$25.60+243.2%-3.0%$421.00MN/A-3.5730Positive NewsPRTCPureTech Health1.7364 of 5 stars$17.49-0.6%$45.00+157.3%-23.3%$418.75M$3.33M0.00100Gap DownHigh Trading Volume Related Companies and Tools Related Companies Sage Therapeutics Competitors Phathom Pharmaceuticals Competitors Esperion Therapeutics Competitors AnaptysBio Competitors GH Research Competitors SIGA Technologies Competitors Alpha Teknova Competitors Zevra Therapeutics Competitors Astria Therapeutics Competitors PureTech Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANRO) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alto Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alto Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
